card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

MASH and Liver Disease Capabilities

MASH and Liver Disease Capabilities
Home / Insights / MASH and Liver Disease Capabilities

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease, affecting up to 30% of the world population. Its effects range from simple fat accumulation (steatosis) to inflammatorymediated fibrosis or cirrhosis – the most severe form of the disease called metabolic dysfunction-associated steatohepatitis (MASH). It is estimated that 20-25% of MASLD patients will advance to MASH during their lifetime, placing them at significantly increased risk for liver failure or liver cancer.

 

As a leading laboratory services organization for trials across the globe, we integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize your MASLD or MASH study design, assuring high-quality data delivery and regulatory approval. Our network of laboratories offers services across the globe including anatomic pathology and biomarker delivery.

 

Download our fact sheet to learn about our capabilities supporting MASH and liver disease clinical trials.


Download Document